Neuronetics Inc (STIM) Stock Forecast & Price Target

Neuronetics is expected to experience continued growth in the psychiatric market with their non-invasive and non-systemic NeuroStar Advanced Therapy System and their newly acquired Greenbrook clinic business. The company's positive Q2 results, expanding customer base, and collaborative efforts in the expanding psychedelic therapy market indicate a promising future for Neuronetics. There are possible risks, but the company's strong financial performance and strategic partnerships make them an attractive investment option in the mental health sector.

Neuronetics is a medical technology company focused on developing products for psychiatric disorders. Despite positive clinical evidence and widespread reimbursement for its NeuroStar TMS therapy, the company's market penetration rate is less than 3%. Its recent acquisition of Greenbrook TMS adds a wider network of treatment centers and a new therapy, SPRAVATO, but the clinic services segment operates at a lower gross margin. Operating expenses were reduced, resulting in positive adj. EBITDA for the first time, but there are potential risks in terms of competition, reimbursement, and regulatory oversight for its potential treatment for PTSD.